Login / Signup

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy.

Emiliano Angeloni
Published in: Core evidence (2016)
Azilsartan is a safe and effective treatment option for every stage of hypertension, both alone or in fixed-dose combination tablets with chlorthalidone or amlodipine. Beneficial effects of AZI were also noted in patients with any degree of renal impairment. In addition, safety profiles of AZI were similar to that of the placebo.
Keyphrases
  • blood pressure
  • hypertensive patients
  • randomized controlled trial
  • stem cells
  • clinical trial
  • mesenchymal stem cells
  • arterial hypertension
  • replacement therapy
  • phase iii
  • cell therapy
  • study protocol